A recent visit to Tokyo and Seoul offered a glimpse into the strategic priorities of LEO Pharma’s Japanese and Korean affiliates as they begin the new year. Discussions with teams on the ground, coupled with meetings at the Embassy of Denmark in Korea, highlighted a clear commitment to patient-centric care and ambitious growth plans within the region.
The focus on translating strategic priorities into tangible action was evident throughout the meetings. LEO Pharma, an independent, research-based pharmaceutical company founded in 1908, is increasingly focused on dermatological and thrombotic treatments, serving patients in over 100 countries globally, according to information from the Danish Chamber of Commerce in Japan. This commitment extends to expanding its reach into new markets and addressing unmet medical needs.
The meetings at the Embassy of Denmark in Korea underscored the importance of sustained collaboration and trust in fostering long-term success. Denmark has a strong diplomatic presence in South Korea, and such engagements are vital for supporting the operations of Danish companies like LEO Pharma within the country. The LEO Foundation, the sole shareholder of LEO Pharma, is independent from external interests, reinforcing the company’s long-term vision and stability, as detailed on the LEO Pharma Japan website.
LEO Pharma’s mission, “we help people achieve healthy skin,” guides its development of comprehensive care solutions tailored to patient needs. This patient-first approach was a recurring theme in conversations with the teams in both Japan and Korea, who expressed a strong dedication to improving the quality of life for individuals facing dermatological challenges.
Expanding Footprint in Key Asian Markets
The Japanese and Korean markets represent significant opportunities for LEO Pharma’s growth strategy. LEO Pharma K.K. Was established in Japan in June 2010 as a wholly-owned subsidiary, aiming to establish a strong position as a specialty pharmaceutical company specializing in dermatology. Both countries have aging populations and increasing rates of skin conditions, creating a growing demand for advanced dermatological treatments. The company’s global team of 6,000 people serves 92 million patients in 130 countries, demonstrating its extensive reach and commitment to global health.
The discussions similarly highlighted the importance of innovation and adaptability in navigating the dynamic pharmaceutical landscape. LEO Pharma emphasizes a culture of innovation, encouraging employees to challenge the status quo and implement new ideas. This commitment to innovation is crucial for developing cutting-edge therapies and maintaining a competitive edge in the market.
Denmark-Korea Collaboration
The engagement with the Embassy of Denmark in Korea signals a broader trend of strengthening diplomatic and economic ties between the two nations. Denmark and South Korea have a long-standing relationship built on shared values and mutual interests. The embassy plays a key role in facilitating trade and investment between the two countries, supporting Danish companies like LEO Pharma in their expansion efforts.
LEO Pharma’s values – integrity, customer focus, innovation, passion, and adaptability – were consistently reflected in the interactions with the teams in Japan and Korea. These values underpin the company’s commitment to responsible business practices and ethical conduct, ensuring compliance and building trust with stakeholders.
Looking ahead, LEO Pharma is poised to continue its growth trajectory in Asia, driven by its patient-centric approach, commitment to innovation, and strong partnerships. The company’s focus on dermatological care and its expanding presence in key markets like Japan and Korea position it as a significant player in the region’s healthcare landscape. The company’s 2025 financial results, recently announced, were described as a “breakthrough year” by CFO Philip Eickhoff, indicating positive momentum and strategic alignment.
What are your thoughts on the growing importance of international collaboration in the pharmaceutical industry? Share your insights in the comments below.
